Home › NDC Lookup › Ingredients › Adapalene › 46122-0768-36
Adapalene 1 mg/g Gel — NDC 46122-0768-36 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Adapalene 1 mg/g Gel — NDC 46122-768-36 (Billing 46122-0768-36)

by AMERISOURCE BERGEN · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of Adapalene 1 mg/g Gel from AMERISOURCE BERGEN, marketed since Feb 2024 and currently FDA-listed; retail pharmacies pay about $0.4655 per g (NADAC). It is this product's only package size.

NDC 46122-0768-36
🏷️ FDA NDC (as labeled) 46122-768-36 billing pads the product segment with a zero
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 46122-768-36
Product NDC 46122-768
11-digit billing NDC 46122076836
NCPDP billing unit GM — per gram (weight)
RxCUI 307731
UNII 1L4806J2QF
Application # ANDA215940
SPL Set ID 8d6e2e28-a11a-4443-a43b-098a55622e24
Established class (EPC) Retinoid
Chemical class Retinoids
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-02-26
Route TOPICAL
Dosage form GEL
Substance ADAPALENE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90050003004010
GCN Seq No 026436
GCN 29300
HICL code 011233
Ingredient (HICL) Adapalene
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L9
Therapeutic class — intermediate (HIC2) Dermatologic Preparations,Miscellaneous
HIC3 code L9B
Therapeutic class — specific (HIC3) Vitamin A Derivatives
AHFS code 84:28.00.00
AHFS class Keratolytic Agents
FDB label name GNP ADAPALENE 0.1% GEL
FDB brand name Adapalene
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 026436
  • GCN: 29300
  • GPI-14 (Medi-Span): 90050003004010
  • HICL (First Databank): 011233
  • AHFS class code: 84:28.00.00
  • RxCUI (RxNorm): 307731
Why two NDCs? The FDA registers this code as 46122-768-36 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 46122-0768-36. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Retinoid class.

Pharmacologic class Retinoid
Drug family (ATC) Retinoids for topical use in acne
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name GNP ADAPALENE 0.1% GEL Ingredient Adapalene
📖 What it is MedlinePlus · NLM

Adapalene is used to treat acne in adults and children 12 years of and older. Adapalene is in a class of medications called retinoid-like compounds. It works by stopping pimples from forming under the surface of the skin.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats acne vulgaris, the common type of acne. Some products are labeled for ages 12 and up. Ask a doctor before using it in younger children.
  • Use it once a day, usually in the evening, on clean, dry skin. Apply a thin layer to the whole affected area and keep it away from your eyes, lips and inside of your mouth or nose....
  • Give it about 8 to 12 weeks. Acne can seem to flare in the early weeks, which is not a reason to stop. If you see no improvement after 12 weeks, talk to your prescriber.
  • Redness, dryness, peeling and some burning or stinging are the most common, especially in the first month. They are usually mild to moderate and often ease. A moisturizer can help....
📖 Read our full Adapalene guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.466 $6.98 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.6121 $9.18 / 15 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.480 $0.432
▼ Down 3% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
46122-0768-36 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE 2024-02-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Adapalene 1 mg/g 00536-1412-20 RUGBY 1 tube $0.466 — Availability likely —
Adapalene 1 mg/gthis 46122-0768-36 AMERISOURCE 1 tube $0.466 — Availability likely —
Adapalene 1 mg/g 51672-2150-01 Sun 1 tube $0.466 — Availability likely —
Adapalene 1 mg/g 70000-0666-01 Cardinal 1 tube $0.466 — Availability likely —
Adapalene 1 mg/g 00168-0424-46 E. 1 tube $2.855 AB Availability likely +513%
Differin 1 mg/g 00299-4910-00 Galderma 1 tube — — FDA listed —
PanOxyl 1 mg/g 00316-0143-15 CROWN 1 tube — — FDA listed —
PanOxyl 1 mg/g 00316-0284-15 CROWN 1 tube — — FDA listed —
Adapalene 1 mg/g 00363-0888-05 Walgreens 1 tube — — FDA listed —
Adapalene 1 mg/g 00363-1401-05 Walgreens 1 tube — — FDA listed —
Adapalene 1 mg/g 00363-4110-05 Walgreens 1 tube — — FDA listed —
Proactiv MD Adapalene Acne Treatment .1 g/100g 11410-0958-15 Alchemee, 1 tube — — FDA listed —
Adapalene 1 mg/g 11822-0062-01 RITE 1 tube — — FDA listed —
Adapalene 1 mg/g 21130-0754-05 Safeway, 1 tube — — FDA listed —
Adapalene 1 mg/g 30142-0725-05 The 1 tube — — FDA listed —
Adapalene 1 mg/g 36800-0088-05 TOP 1 tube — — Discontinued —
Adapalene 1 mg/g 41250-0288-05 MEIJER, 1 tube — — FDA listed —
Adapalene 1 mg/g 49967-0354-01 LOreal 1 tube — — FDA listed —
Effaclar 1 mg/g 49967-0591-01 LOreal 1 tube — — FDA listed —
Effaclar 1 mg/g 49967-0592-01 LOreal 1 tube — — FDA listed —
Adapalene 1 mg/g 51316-0114-05 CVS 1 tube — — FDA listed —
Adapalene 1 mg/g 55910-0880-05 Dolgencorp, 1 tube — — FDA listed —
Adapalene 1 mg/g 59726-0114-05 P 1 tube — — FDA listed —
Adapalene 1 mg/g 59726-0888-05 P 1 tube — — Discontinued —
Adapalene 1 mg/g 69842-0088-05 CVS 1 tube — — FDA listed —
Neutrogena Adapalene 0.1% Acne Treatment 1 mg/g 69968-0826-01 Kenvue 1 tube — — FDA listed —
Neutrogena Evenly Clear Retinoid Adapalene Gel 0.1% Acne Treatment 1 mg/g 69968-0945-02 Kenvue 1 tube — — FDA listed —
Neutrogena Evenly Clear Retinoid Adapalene Gel 0.1% Acne Treatment 1 mg/g 69968-1004-02 Kenvue 1 tube — — FDA listed —
Curist Acne Relief .1 g/100g 72559-0015-13 Little 1 tube — — FDA listed —
Adapalene 1 mg/g 72657-0158-15 GLENMARK 1 bottle — — FDA listed —
Adapalene 1 mg/g 73581-0019-06 YYBA 1 tube — — FDA listed —
Adapalene 1 mg/g 73581-0214-06 YYBA 1 tube — — FDA listed —
Adapalene 1 mg/g 73581-0215-45 YYBA 1 tube — — FDA listed —
Adapalene 1 mg/g 73581-0216-45 YYBA 1 tube — — FDA listed —
Adapalene Gel 0.1% .1 g/100g 73715-0003-01 MOHNARK 30 g — — Discontinued —
Adapalene 1 mg/g 76162-0114-05 Topco 1 tube — — FDA listed —
Adapalene 1 mg/g 79481-1140-05 Meijer 1 tube — — FDA listed —
Adapalene 1 mg/g 79903-0338-05 Wal-Mart 1 tube — — FDA listed —
Adapalene 1 mg/g 82442-0105-01 Target 1 tube — — FDA listed —
Adapalene 1 mg/g 72162-1048-02 Bryant 1 tube — AB FDA listed —
Adapalene 1 mg/g 63629-8791-01 Bryant 1 tube — AB FDA listed —
Adapalene Paraben Free 1 mg/g 76162-0221-05 Topco 1 tube — — FDA listed —
Adapalene Paraben Free 1 mg/g 79481-2210-05 Meijer 1 tube — — FDA listed —
Adapalene Paraben Free 1 mg/g 30142-0542-05 The 1 tube — — FDA listed —
Adapalene Paraben Free 1 mg/g 51316-0219-05 CVS 1 tube — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Feb 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAMERISOURCE BERGEN
Application holderSUN PHARMA CANADA INC
FDA applicationANDA215940 (ANDA)
Labeler code46122
First marketedFeb 2024
Product typeHuman Otc Drug
Portfolio206 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 6 words ▾

Use For the treatment of acne

⏱️ Dosage and Administration 83 words ▾

Directions Adults and children 12 years of age and older: use once daily clean the skin gently and pat dry before applying the product cover the entire affected area with a thin layer. For example, if your acne is on the face, apply the product to the entire face. do not use more than one time a day. Applying more than directed will not provide faster or better results, but may worsen skin irritation. Children under 12 years of age: ask a doctor

⚠️ Warnings ~1 min read ▾

Warnings For external use only Do not use on damaged skin (cuts, abrasions, eczema, sunburn) if you are allergic to adapalene or any of the ingredients in this product. If pregnant or breast-feeding, ask a doctor before use. When using this product limit sun exposure, including light from tanning beds, and use sunscreen when going outdoors do not wax to remove hair in areas where the product has been applied during the early weeks of use, your acne may appear to worsen before it improves (this is normal); continue using as directed, unless you get irritation that becomes severe irritation (redness, itching, dryness, burning) is more likely to occur: in the first few weeks of use if using more than one topical acne medication at a time but irritation usually lessens with continued use of this product it may take up to 3 months of once daily use to see results avoid product contact with eyes, lips, and mouth.

If contact occurs, immediately flush the area with water. wash hands after use Stop use and ask doctor if you become pregnant, or are planning to become pregnant, while using the product you have symptoms of an allergic reaction (such as itching, rash, hives, swelling of the lips, eyelids, and shortness of breath) irritation becomes severe you see no improvement after 3 months of once daily use Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 34 words ▾

Other information TAMPER EVIDENT: DO NOT USE IF THE SEAL ON THE TUBE IS PUNCTURED OR NOT VISIBLE. store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. protect from freezing

🧪 Active Ingredient 10 words ▾

Active ingredient Adapalene USP, 0.1% (retinoid) read consumer information leaflet

🧪 Inactive Ingredients 17 words ▾

Inactive ingredients carbomer homopolymer type C, edetate disodium, phenoxyethanol, poloxamer 182, propylene glycol, purified water, sodium hydroxide.

🎯 Purpose 3 words ▾

Purpose Acne treatment

📄 Do Not Use 24 words ▾

Do not use on damaged skin (cuts, abrasions, eczema, sunburn) if you are allergic to adapalene or any of the ingredients in this product.

📄 When Using This Product 134 words ▾

When using this product limit sun exposure, including light from tanning beds, and use sunscreen when going outdoors do not wax to remove hair in areas where the product has been applied during the early weeks of use, your acne may appear to worsen before it improves (this is normal); continue using as directed, unless you get irritation that becomes severe irritation (redness, itching, dryness, burning) is more likely to occur: in the first few weeks of use if using more than one topical acne medication at a time but irritation usually lessens with continued use of this product it may take up to 3 months of once daily use to see results avoid product contact with eyes, lips, and mouth.

If contact occurs, immediately flush the area with water. wash hands after use

📄 Stop Use and Ask a Doctor If 54 words ▾

Stop use and ask doctor if you become pregnant, or are planning to become pregnant, while using the product you have symptoms of an allergic reaction (such as itching, rash, hives, swelling of the lips, eyelids, and shortness of breath) irritation becomes severe you see no improvement after 3 months of once daily use

🤰 If Pregnant or Breast-Feeding 9 words ▾

If pregnant or breast-feeding, ask a doctor before use.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Questions or Comments 2 words ▾

Questions? 1-866-923-4914

📄 Package Label / Principal Display Panel 65 words ▾

PRINCIPAL DISPLAY PANEL - 15 g Tube Carton NDC 46122-768-36 Compare to the Differin ® Gel † active ingredient GOOD NEIGHBOR PHARMACY ® PARABEN FREE Adapalene Gel USP, 0.1% Acne Treatment Previously available only by prescription FDA approved Dermatologist developed Once Daily Topical Retinoid* * Read consumer information leaflet before use NET WT 0.5 oz (15 g) PRINCIPAL DISPLAY PANEL - 15 g Tube Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
787
Units reimbursed last 4 qtrs
21K
Gross reimbursed last 4 qtrs
$12.9K
Avg / prescription
$16.33
Avg / unit
$0.6121
Latest quarter Q1 2026
234Rx
Medicaid pays / g
$0.6121
gross reimbursed
vs
NADAC / g
$0.4655
acquisition cost
=
Spread
+$0.1466
+31% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
46% FFS 54% MCO
Fee-for-service · 365 Rx Managed care · 422 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 825 units · 8.2 per 100k residents MI New York: 2,115 units · 10.8 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 6,855 units · 73.8 per 100k residents NJ Massachusetts: no data reported MA California: 10,530 units · 27.0 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 675 units · 18.7 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
8.273.8
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 73.8 /100k
2 California 27.0 /100k
3 Connecticut 18.7 /100k
4 New York 10.8 /100k
5 Michigan 8.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Adapalene — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Adapalene. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$999.6K
Claims incl. refills
2.4K
Beneficiaries
1.8K
Spend / beneficiary
$553.81
Spend / claim
$410.69
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 46122-0767-11 · Amerisource 46122-0769-64 · AmerisourceBergen →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.